Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Ovarian Cancer Metastatic × Cyclophosphamide × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 491 Lymphoma 405 Precursor Cell Lymphoblastic Leukemia-Lymphoma 366 Lymphoma, Large B-Cell, Diffuse 320 Leukemia 318 Multiple Myeloma 305 Lymphoma, Non-Hodgkin 287 Leukemia, Lymphocytic, Chronic, B-Cell 260 Leukemia, Myeloid, Acute 256 Lymphoma, Follicular 222 Burkitt Lymphoma 198 Myelodysplastic Syndromes 191 Lymphoma, Mantle-Cell 184 Hodgkin Disease 179 Recurrence 138 Lymphoma, B-Cell, Marginal Zone 131 Melanoma 126 Lymphoma, Large-Cell, Immunoblastic 108 Neoplasms 100 Lymphoma, B-Cell 93 Neoplasms, Plasma Cell 91 Neuroblastoma 87 Ovarian Neoplasms 83 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 81 Hematologic Neoplasms 78 Triple Negative Breast Neoplasms 77 Myeloproliferative Disorders 77 Leukemia, Myeloid, Chronic-Phase 75 Leukemia, Myeloid, Accelerated Phase 75 Dendritic Cell Sarcoma, Interdigitating 73

Interventions

fludarabine 1 aldesleukin 1 Interleukin-2 1 Cyclophosphamide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04389229 2020-12-16

OVSTAR

Immetacyte Ltd

Phase 1/2 Withdrawn

Ovarian Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡